AstraZeneca (LON:AZN) has been given a GBX 4,080 ($53.31) price objective by Goldman Sachs Group in a report issued on Thursday, September 20th. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group’s price objective would suggest a potential downside of 26.43% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Tuesday, June 5th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 26th. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,000 ($78.40) target price on shares of AstraZeneca in a research report on Friday, July 27th. Cfra set a GBX 5,000 ($65.33) price objective on shares of AstraZeneca and gave the stock a “neutral” rating in a research report on Wednesday, May 23rd. Finally, UBS Group restated a “neutral” rating and set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca in a research report on Monday, July 2nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 5,700.70 ($74.49).

Shares of LON AZN traded down GBX 70 ($0.91) during mid-day trading on Thursday, reaching GBX 5,546 ($72.47). The company’s stock had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: How to Use the New Google Finance Tool

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.